Skip to content
Open access

Reduced Expression of Brain Expressed X-linked Genes in Alzheimer’s Disease

Aug 2026 · Journal of Alzheimer's Disease · Vol 113, pp. 835 - 851 · 0 citations · 75 references
Medicine

TL;DR

It is suggested that reduced BEX expression in neurons appears to be a contributing factor to AD pathogenesis and BEX depletion may increase oxidative stress.

Abstract

Background Altered expression of Brain Expressed X-linked (BEX) genes has been implicated in Alzheimer's disease (AD) with inconsistencies and a lack of experimental confirmation. Objective This study aims to characterize BEX expression patterns, examine the association of their expression with AD pathology, and investigate cellular changes induced by altered BEX expression. Methods We integrated bulk and single-cell transcriptomics datasets to characterize cortical BEX expression changes in 5xFAD mice and AD patients, which were validated by RT-qPCR in postmortem AD cortical tissue. We manipulated the expression of BEX genes in SH-SY5Y cells and examined changes in oxidative stress. Results Cortical expression of BEX genes was reduced in AD. With the dysregulation being more pronounced at a later stage of the disease, the reduction was closely related to the impairment of synaptic transmission and oxidative phosphorylation in excitatory neurons. Consistent with these, BEX3 knockdown increased oxidative stress. Conclusions Our findings suggest that reduced BEX expression in neurons appears to be a contributing factor to AD pathogenesis and BEX depletion may increase oxidative stress.

Read PDF

Similar papers

Oct 2026

Differential effects of amyloid-β and tau on UCH gene expression in Drosophila models of Alzheimer's disease.

BACKGROUND Alzheimer's disease (AD) is a common neurodegenerative disorder characterized by progressive impairments in learning and memory. Substantial evidence indicates that dysfunction of the ubiquitin-proteasome system (UPS) in the AD brain leads to aberrant protein aggregation, ultimately resulting in synaptic dys...

Mohammad Javad Arayesh, Fatemeh Ataellahi, R. Masoudi · 0 citations
Review Open access Aug 2026

Novel cell markers with altered expression in brain aging and Alzheimer's disease: A review

This review aims to compile recent markers of aging and Alzheimer's disease in immune, glial, and neuronal cells, which are increasingly vital for enhancing diagnostic precision and monitoring disease progression.

Ejiofor J. Alobu, O. Uchewa, A. Ibegbu · 0 citations
Open access Aug 2026

Brain multiomic profiling identifies tau-related transcriptomic dysregulation in Alzheimer’s disease

A hypothetical model of dynamic brain gene expression changes that track with progressive Alzheimer’s disease proteostasis is proposed and found that a beneficial brain biochemical state of higher total tau and lower phospho-Tau is associated with increased levels of synaptic, DNA damage/repair, nucleic acid metabolism...

Stephanie R. Oatman, Zachary S. Quicksall, Xue Wang et al. · 0 citations
Open access Sep 2026

Single-cell transcriptomic atlas of Alzheimer's disease middle temporal gyrus reveals region, cell type, and sex specificity of gene expression with novel genetic risk for MERTK in female

A single cell atlas of middle temporal gyrus revealed a unique cellular-level view of sex-specific transcriptional changes in AD, illuminating GWAS identification of sex-specific AD genes.

Le Zhang, Tian-Yu Liu, Chuan He et al. · 1 citation
Review Open access Sep 2026

Alzheimer's disease-associated transcriptional signatures define prognostic subtypes in glioma.

BACKGROUND Gliomas are molecularly heterogeneous central nervous system tumors with marked variation in clinical outcome. Alzheimer's disease (AD)-associated transcriptional alterations may capture neural and immune programs relevant to glioma biology, but they do not by themselves establish a direct mechanistic relati...

Jun-Wu Fu, Xiang-Qian Ren, Cheng-Yong Yang et al. · 0 citations
Sep 2026

Allele-specific expression modulates the immunological and cis-regulatory landscape of Parkinson's Disease.

Results support the view that ASE captures a broad regulatory signature in iPD, distinct from the DNA methylation context, and reinforces the role of immunogenetic dysregulation as a primary component of the disease's pathophysiology, offering new targets for mechanistic investigation and peripheral biomarkers.

R. M. Piergiorge, Alan Tardin da Silva, Ronaldo Francisco et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.